of Sandoz in Switzerland managing launch and growth of global products in the field of immunology and dermatology. She joined Sandoz in South Africa in 1988 as a clinical researcher and expanded her résumé to include portfolio and specialty market management. Dr. Dunsire is a member of the board of directors of Allergan Inc. and serves as a director of the Biotechnology Industry Organization where she co-chairs the Committee on Reimbursement and serves as a member of the executive committee. Her not-for-profit board memberships include CancerCare Inc.; the Gabrielle’s Angel Foundation for Cancer Research; and the Boston Museum of Science, where she chairs the investment review board; and she is also a member of the Massachusetts General Hospital research advisory council. She served as a director of the Pharmaceutical Research and Manufacturers of America from 2005 to 2008 and as a director of the California Healthcare Institute from 2002 to 2005. Dr. Dunsire was the 2001 recipient of the American Cancer Society Excalibur Award, the 2000 recipient of the Health Care Business Women’s Association Rising Star Award, the 2009 Health Care Business Women’s Association Woman of the Year Award, the 2011 Massachusetts Biotechnology Organization’s Innovative Leadership Award, and the 2011 Golden Door Award from the International Institute of New England. She received a Ph.D. honoris causa from Worcester Polytechnic Institute in 2007. Dr. Dunsire graduated as a physician from the University of Witwatersrand in Johannesburg, South Africa.
Victor J. Dzau, M.D., is the chancellor for health affairs and James B. Duke Professor of Medicine at Duke University and the president and chief executive officer of Duke University Health System. Dr. Dzau was previously the Hersey Professor of Theory and Practice of Medicine and chairman of medicine at Harvard Medical School’s Brigham and Women’s Hospital and the chairman of the department of medicine at Stanford University. Dr. Dzau has made a significant impact on medicine through his seminal research in cardiovascular medicine, his pioneering work in the discipline of vascular medicine, and recently his leadership in health care innovation. His important work on the renin angiotensin system (RAS) paved the way for the contemporary understanding of RAS in cardiovascular disease and the development of RAS inhibitors as therapeutics. Dr. Dzau also pioneered gene therapy for vascular disease and was the first to introduce DNA decoy molecules to block transcription as gene therapy in vivo. Recently his seminal work on stem cell “paracrine mechanism” provided novel insights into stem cell biology and therapy. As a leader of academic medicine, Dr. Dzau’s vision is that academic health centers must lead the transformation through innovation, translation, and globalization. To achieve this vision he has established the Duke Translational Medicine Institute, Duke Global Health Institute, Duke Initiative in Health Innovation, and Duke National Univer-